Rakesh Patel, MD
Nephrology · Gallup, NMNPI 1508069725
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $203 of the $265 with a category attached, or 76.9%. 5 manufacturers reported payments, led by AbbVie at 50.0% of the total. Reporting peaked in 2021 at $114 and has fallen 79.3% since, to $24 in 2025. That places this record below the midpoint for nephrology clinicians in NM, where the typical reported total is $1,114.
Across 6 payments — averaging $44.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$132
- Otsuka America Pharmaceutical, Inc.$61
- Baxter Healthcare$30
- Akebia Therapeutics Inc$24
- Ardelyx, Inc.$17
What the payments were for
- Food & beverage$20377%
- Education$6123%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 2 | $132 |
| Otsuka America Pharmaceutical, Inc. | 1 | $61 |
| Baxter Healthcare | 1 | $30 |
| Akebia Therapeutics Inc | 1 | $24 |
| Ardelyx, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$114
How this compares
$265 in reported general payments places this provider in the 20th percentile of 68 nephrology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sevelamer Carbonate | 100 | $43,005 |
| ClinisolParenteral Amino Acid 15% No.5 | 59 | $6,459 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 15 | $4,063 |
| Losartan Potassium | 49 | $383 |
| Atorvastatin Calcium | 38 | $229 |
| Chlorthalidone | 12 | $175 |
| Lisinopril | 22 | $155 |
| Furosemide | 16 | $115 |
| Amlodipine Besylate | 31 | $82 |
| Carvedilol | 17 | $58 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Gallup
- Oladipo AdeniyiGallup$302
- Satyaki BanerjeeAlbuquerque$260K
- Catalina VoinescuSanta Fe$41K
- Christos ArgyropoulosAlbuquerque$32K
- Arun RajasekaranAlbuquerque$32K
- Jose HenaoLas Cruces$31K
- George Vasquez RiosAlbuquerque$25K
- Jayant KumarAlbuquerque$12K
- Milagros Samaniego-PicotaRoswell$11K
- Luis Madera MarinAlbuquerque$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.